No Data
No Data
No Data
No Data
No Data
Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the compan
BenzingaApr 25 16:40 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
BenzingaApr 23 16:31 ET
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Yahoo FinanceApr 23 09:40 ET
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
Yahoo FinanceApr 4 09:40 ET
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
TipRanksMar 27 21:50 ET
Adverum Biotechnologies Files for $200M Mixed Securities Shelf
Seeking AlphaMar 21 17:40 ET
QianmengYu : nice!
QianmengYu : drop to halt. Hmmm
QianmengYuOP : so strange. If insider knew data is so great, they won’t finance at 1.2 with almost 100% dilution, Private placement will get 50% shares thereafter, insider get somewhat. That’s more shares than they can dump to open market. what’s point to pump to 2.8? I don’t think in current US regulations, someone can take over a company simply just by private share issuing and collecting sufficient shares on open market (allowed in some countries). Let’s see.
QianmengYu : thank you. I am not surprised. Nasty.
Stock_Drift : Judging by pre_market I’d say it’s a Go!!
MangoXXXXOP Stock_Drift: More news coming this week. So maybe Im holding !
Stock_Drift : Yes!!!
No Data
No Data